Trial Profile
Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 24 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2013 New trial record